TAT Peptide-Coated Nanoparticles Deliver Gene-Silencing Therapy to the Lungs for Asthma

The study involved multi-step polymer synthesis: first creating a protonable copolymer from PHEA backbone with amine and PEG modifications, then complexing it with siRNA to form nanosized polyplexes, and finally decorating them with thiolated TAT peptide. Testing included mucus diffusion assays, cytocompatibility studies, cellular uptake imaging in bronchial epithelial cells, IL-8 gene expression measurement after LPS stimulation, and spray freeze drying to create inhalable microparticles. All experiments were conducted in vitro.

Current asthma treatments primarily manage symptoms rather than targeting the underlying inflammatory gene expression. Inhaled siRNA therapy could silence specific genes driving inflammation, but the lung's mucus barrier makes delivery extremely challenging. Using TAT peptide as a cell-penetrating agent to overcome this barrier represents a creative approach that could open the door to gene-level asthma treatments delivered conveniently as dry powder inhalers.

Cell-penetrating peptides like TAT are gaining traction as delivery tools across many therapeutic areas. This work applies them to the challenging problem of inhaled gene therapy, where the mucus barrier, immune clearance, and need for precise lung deposition all complicate delivery. If inhalable siRNA formulations can be made practical, they could transform treatment of asthma and other respiratory inflammatory diseases by targeting root causes rather than just symptoms.

All experiments were conducted in vitro — no animal studies or human testing was performed. Mucus diffusion was tested with purified mucin rather than native airway mucus, which is more complex. IL-8 knockdown was demonstrated after artificial LPS stimulation, which may not fully replicate asthma pathophysiology. The aerodynamic performance of the microparticles was characterized technically but not tested in an actual inhalation model.